Form 8-K - Current report:
SEC Accession No. 0000950170-24-092272
Filing Date
2024-08-07
Accepted
2024-08-07 07:10:08
Documents
14
Period of Report
2024-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kymr-20240807.htm   iXBRL 8-K 49481
2 EX-99.1 kymr-ex99_1.htm EX-99.1 143186
3 GRAPHIC img100385778_0.jpg GRAPHIC 25720
4 GRAPHIC img100385778_1.jpg GRAPHIC 25720
  Complete submission text file 0000950170-24-092272.txt   400744

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kymr-20240807.xsd EX-101.SCH 31101
16 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20240807_htm.xml XML 4716
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 241181407
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)